Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prophylactic/therapeutic agent for cardiovascular complications of diabetes

一种糖尿病性、心血管的技术，应用在心血管系统疾病、泌尿系统疾病、代谢疾病等方向，能够解决外科治疗方法得不到充分治疗效果、无法抑制心血管并发症发病等问题，达到优良预防或治疗效果、改善预防或治疗、显著预防或治疗的效果

Inactive Publication Date: 2014-07-23
OSAKA UNIV
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, for diabetic patients, even strong suppression of the above risk factors cannot suppress the onset of cardiovascular complications
In addition, as a treatment for arteriosclerosis, there are also surgical treatments (for example, coronary angioplasty, bypass surgery), but for diabetic arteriosclerosis, surgical treatments cannot achieve sufficient therapeutic effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic/therapeutic agent for cardiovascular complications of diabetes
  • Prophylactic/therapeutic agent for cardiovascular complications of diabetes
  • Prophylactic/therapeutic agent for cardiovascular complications of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0106]Next, the present invention is described in more detail by enumerating experimental examples and examples, but the present invention is not limited by these examples, and those skilled in the art can understand the technical ideas of the present invention Make a lot of deformations.

experiment example 1

[0109] The hearts of 10 above-mentioned diabetic patients who died of heart disease despite adequately receiving existing treatments were dissected. Below, clinical manifestations and pathological results are shown.

[0110] The mean BMI of the cases was 21.3. The clinical diagnosis was myocardial infarction, angina pectoris, heart failure, etc. The duration of diabetes was 15.3±9.7 years. Treated with insulin or oral hypoglycemic drugs. Lipid abnormalities were treated with statins and fibrates. Serum LDL-cholesterol was 96.2±17 (reference value: below 140mg / dL), serum TG was 126±41 (reference value: below 150mg / dL), and the control good. The weight of the dissected heart was heavy (534.5±87 g), and plaques were formed on three coronary arteries in all cases, and diffuse concentric stenosis was confirmed. Part of the myocardium was fibrotic, and an infarct was confirmed. The reference value of heart weight is 272±1.5 g for men and 233±1.5 g for women (Japanese Society o...

experiment example 2

[0113] In addition to the above-mentioned diabetic patient group and the above-mentioned non-diabetic patient group, as a representative example of cholesterol-induced arteriosclerosis, using 3 anatomical samples of familial hypercholesterolemia (FH) (n=3), neutral fat and Cholesterol accumulation was analyzed. show the result in figure 1 . In the figure, A represents the amount of neutral fat in the myocardium (mg / tissue g), B represents the amount of cholesterol in the myocardium (mg / tissue g), and C represents the amount of neutral fat in the coronary artery (mg / tissue g). g), D represents the amount of cholesterol in coronary arteries (mg / tissue g). Non DM means non-diabetic patients, DM means diabetic patients, FH means familial hypercholesterolemia patients. In the figure, * indicates statistical significance (p<0.001, Dunnett's type test) relative to the other two data.

[0114] Depend on figure 1 The results showed that neutral fat (TG) was significantly accumulat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a drug having excellent prophylactic or therapeutic effect against cardiovascular complications of diabetes, the drug containing a compound for inhibiting neutral fat accumulation in cardiovascular tissue or cells. The present invention pertains to a prophylactic / therapeutic drug for cardiovascular complications of diabetes, the drug containing a compound for inhibiting neutral fat accumulation (preferably, medium-chain fatty acid and / or medium-chain triglyceride).

Description

technical field [0001] The present invention relates to a preventive / therapeutic agent for diabetic cardiovascular complications. More specifically, it relates to the prevention / prevention of diabetic cardiovascular complications containing a compound having neutral fat accumulation inhibitory or decomposing ability in cardiovascular tissue or cells, neutral fat metabolism improving ability, and vascular function improving effect. therapeutic agent. Background technique [0002] Conventionally, attention has been paid to cholesterol as a lipid that causes congestive heart failure, arteriosclerosis, dementia, etc. For example, arteriosclerosis is thought to be caused by accumulation of cholesterol in the subintima of blood vessels. Therefore, in order to prevent or treat these diseases, various pharmaceutical preparations have been developed with cholesterol as a target, represented by statins (for example, Patent Documents 1 to 3). [0003] It is known that by using these ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/19A61K31/20A61K31/215A61K31/23A61K45/00A61P3/06A61P3/10A61P9/00A61P9/04A61P9/06A61P9/10A61P13/12A61P25/00A61P27/02
CPCA61K31/19A61K31/20A61K31/215A61K31/23A61P3/06A61P3/10A61P9/00A61P9/04A61P9/06A61P9/10A61P13/12A61P25/00A61P27/02A61K2300/00
Inventor 平野贤一安井洋子池田善彦濑藤光利财满信宏
Owner OSAKA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com